Although, as a commonly altered gene like TP53, KRAS, and EGFR in LUAD,10 changes within tumor immune milieu, and accordingly the clinical implication relevant to the mutation of KEAP1, remains largely unknown. This evidence concerns the gene KEAP1 and neoplasm.